Press "Enter" to skip to content

FDA expands approval of treatment for cystic fibrosis to include patients ages 6 and older

FDA expanded the indication for Symdeko for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.

Original source: http://www.fda.gov/news-events/press-announcements/fda-expands-approval-treatment-cystic-fibrosis-include-patients-ages-6-and-older

Also Read:   Coronavirus (COVID-19) Update: Daily Roundup October 6, 2020